SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences
9 references·0 citing·29 second hop
A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences (2006)A therapeutic substitution policy for pro…The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending (2003)The Effect of Incentive-Based…Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers (2003)Clinical and economic consequ…Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors (2002)Outcomes of Reference Pricing…Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. (2002)Impact of reference-based pri…Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. (2001)Impact of reference-based pri…Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization (2001)Effect of a Three-Tier Prescr…Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons (2001)Adverse Events Associated Wit…Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. (1993)Trends and determinants of pr…Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes (1991)Effects of Medicaid Drug-Paym…Health insurance and the demand for medical care: evidence from a randomized experiment. (1987)Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000 (2005)The effects of prescription drug cost sharing: a review of the evidence. (2005)The Effect of Medicare Part D on Pharmaceutical Prices and Utilization (2010)Payment Restrictions for Prescription Drugs under Medicaid (1987)METHODS FOR ANALYZING HEALTH CARE UTILIZATION AND COSTS (1999)Proposal of the Physicians' Working Group for Single-Payer National Health Insurance (2003)Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid (2004)The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)Pharmaceutical Reference Prices (1998)Review and Update (2003)Pharmaceutical Pricing and Reimbursement Policies in Canada (2009)Price regulation of drugs: Lessons from Germany (1996)The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules (1996)Quantifying Components of Drug Expenditure Inflation: The British Columbia Seniors' Drug Benefit Plan (2002)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Pharmacy Benefits and the Use of Drugs by the Chronically Ill (2004)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization (1990)Estimating the Burden of Disease (1997)Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors (2004)What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries (2008)Pharmaceutical policies: effects of cap and co-payment on rational use of medicines (2015)Ethnic Disparities in Diabetic Complications in an Insured Population (2002)Cost-Related Medication Underuse Among Chronically III Adults: the Treatments People Forgo, How Often, and Who Is at Risk (2004)Unintended Consequences of Caps on Medicare Drug Benefits (2006)The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany (2009)The impact of reference-pricing systems in Europe: a literature review and case studies (2011)
this work references cited by second hop

References

  • 2001Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons873 cited
  • 1991Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes505 cited
  • 2003The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending334 cited
  • 2002Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors178 cited
  • 2001Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization161 cited
  • 1993Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.61 cited
  • 2002Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.60 cited
  • 2001Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.60 cited
  • 2003Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers59 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work